Trial · NCT04179474
Results by group80
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 80
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time t (AUC0-t) for Ubrogepant Alone and in Combination With Erenumab | Part 1: Ubrogepant Alone | 1841.42 | Standard Deviation 490.17 | nanogram*hour/milliliter (ng*h/mL) | |
| Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time t (AUC0-t) for Ubrogepant Alone and in Combination With Erenumab | Part 1: Ubrogepant in Combination With Erenumab | 1959.96 | Standard Deviation 639.51 | nanogram*hour/milliliter (ng*h/mL) | |
| Part 2: AUC0-t for Ubrogepant Alone and in Combination With Galcanezumab | Part 2: Ubrogepant Alone | 1700.31 | Standard Deviation 913.42 | ng*h/mL | |
| Part 2: AUC0-t for Ubrogepant Alone and in Combination With Galcanezumab | Part 2: Ubrogepant in Combination With Galcanezumab | 1758.05 | Standard Deviation 1033.44 | ng*h/mL | |
| Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC0-∞) for Ubrogepant Alone and in Combination With Erenumab | Part 1: Ubrogepant Alone | 1878.25 | Standard Deviation 497.82 | ng*h/mL | |
| Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC0-∞) for Ubrogepant Alone and in Combination With Erenumab | Part 1: Ubrogepant in Combination With Erenumab | 1993.40 | Standard Deviation 639.22 | ng*h/mL | |
| Part 2: AUC0-∞ for Ubrogepant Alone and in Combination With Galcanezumab | Part 2: Ubrogepant Alone | 1732.22 | Standard Deviation 928.06 | ng*h/mL | |
| Part 2: AUC0-∞ for Ubrogepant Alone and in Combination With Galcanezumab | Part 2: Ubrogepant in Combination With Galcanezumab | 1793.74 | Standard Deviation 1057.02 | ng*h/mL | |
| Part 1: Maximum Plasma Drug Concentration (Cmax) for Ubrogepant Alone in Combination With Erenumab | Part 1: Ubrogepant Alone | 459.32 | Standard Deviation 168.56 | ng/mL | |
| Part 1: Maximum Plasma Drug Concentration (Cmax) for Ubrogepant Alone in Combination With Erenumab | Part 1: Ubrogepant in Combination With Erenumab | 486.80 | Standard Deviation 201.52 | ng/mL | |
| Part 2: Cmax for Ubrogepant Alone and in Combination With Galcanezumab | Part 2: Ubrogepant Alone | 415.34 | Standard Deviation 225.64 | ng/mL | |
| Part 2: Cmax for Ubrogepant Alone and in Combination With Galcanezumab | Part 2: Ubrogepant in Combination With Galcanezumab | 375.12 | Standard Deviation 152.08 | ng/mL | |
| Part 1: Time of Maximum Plasma Drug Concentration (Tmax) for Ubrogepant Alone and in Combination With Erenumab | Part 1: Ubrogepant Alone | 1.50 | Full Range 1.00 to 3.00 | hour | |
| Part 1: Time of Maximum Plasma Drug Concentration (Tmax) for Ubrogepant Alone and in Combination With Erenumab | Part 1: Ubrogepant in Combination With Erenumab | 1.48 | Full Range 0.50 to 3.02 | hour | |
| Part 2: Tmax for Ubrogepant Alone and in Combination With Galcanezumab | Part 2: Ubrogepant Alone | 1.50 | Full Range 1.00 to 6.00 | hour | |
| Part 2: Tmax for Ubrogepant Alone and in Combination With Galcanezumab | Part 2: Ubrogepant in Combination With Galcanezumab | 1.50 | Full Range 0.98 to 6.00 | hour | |
| Part 1: Terminal Elimination Rate Constant (λz) for Ubrogepant Alone and in Combination With Erenumab | Part 1: Ubrogepant Alone | 0.136 | Standard Deviation 0.025 | 1/hour | |
| Part 1: Terminal Elimination Rate Constant (λz) for Ubrogepant Alone and in Combination With Erenumab | Part 1: Ubrogepant in Combination With Erenumab | 0.156 | Standard Deviation 0.034 | 1/hour | |
| Part 2: λz for Ubrogepant Alone and in Combination With Galcanezumab | Part 2: Ubrogepant Alone | 0.150 | Standard Deviation 0.053 | 1/hour | |
| Part 2: λz for Ubrogepant Alone and in Combination With Galcanezumab | Part 2: Ubrogepant in Combination With Galcanezumab | 0.165 | Standard Deviation 0.056 | 1/hour |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04179474/results